2023年，君实生物收入增长58%至15亿元人民币，拓益®销售额增长25%至9.19亿元人民币。 2023 Junshi Biosciences reports 58% revenue increase to RMB1.5bn, with TUOYI® sales up 25% to RMB919m.
中国领先的生物制药公司君实生物公布，2023年医药产品收入增长58%，达到约15亿元人民币。 Leading Chinese biopharmaceutical company Junshi Biosciences reported a 58% increase in revenue from pharmaceutical products in 2023, reaching approximately RMB1.5 billion. 拓益®（特瑞普利单抗）销售收入增长25%至约人民币9.19亿元。 Sales revenue of TUOYI® (toripalimab) increased by 25% to around RMB919 million. 公司研发费用下降19%至19.37亿元。 The company's R&D expenses decreased by 19% to RMB1.937 billion. 君实生物正在针对恶性肿瘤、自身免疫性疾病、慢性代谢性疾病、神经系统疾病和感染性疾病等五个主要治疗领域开发创新疗法和新药。 Junshi Biosciences is developing innovative therapies and novel drugs for five major therapeutic areas, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases, and infectious diseases.